Pediatrics

Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.

Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.

Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.

Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.

Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.

Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.

Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.

Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

This program provides awareness of the frontline therapeutic options for pediatric patients. Though current treatments are efficacious, creating a greater understanding of optimizing care while minimizing long-term toxicity from chemotherapy and radiation is critical. This clinician educational program focuses on implementing anti-CD30 targeted therapies effectively to change the disease trajectory for pediatric high-risk cHL. It provides an understanding of the expected adverse event profile of the disease and the overlap with novel therapies as we start using these emerging strategies to maximize our outcomes for the patients.

Don’t miss two additional resources that complement this program: an interactive primary treatment dosing guide; and a patient education handout. Click the Documents tab above to access.

This program provides awareness of the frontline therapeutic options for pediatric patients. Though current treatments are efficacious, creating a greater understanding of optimizing care while minimizing long-term toxicity from chemotherapy and radiation is critical. This clinician educational program focuses on implementing anti-CD30 targeted therapies effectively to change the disease trajectory for pediatric high-risk cHL. It provides an understanding of the expected adverse event profile of the disease and the overlap with novel therapies as we start using these emerging strategies to maximize our outcomes for the patients.

Don’t miss two additional resources that complement this program: an interactive primary treatment dosing guide; and a patient education handout. Click the Documents tab above to access.

This program provides awareness of the frontline therapeutic options for pediatric patients. Though current treatments are efficacious, creating a greater understanding of optimizing care while minimizing long-term toxicity from chemotherapy and radiation is critical. This clinician educational program focuses on implementing anti-CD30 targeted therapies effectively to change the disease trajectory for pediatric high-risk cHL. It provides an understanding of the expected adverse event profile of the disease and the overlap with novel therapies as we start using these emerging strategies to maximize our outcomes for the patients.

Don’t miss two additional resources that complement this program: an interactive primary treatment dosing guide; and a patient education handout. Click the Documents tab above to access.

This program provides awareness of the frontline therapeutic options for pediatric patients. Though current treatments are efficacious, creating a greater understanding of optimizing care while minimizing long-term toxicity from chemotherapy and radiation is critical. This clinician educational program focuses on implementing anti-CD30 targeted therapies effectively to change the disease trajectory for pediatric high-risk cHL. It provides an understanding of the expected adverse event profile of the disease and the overlap with novel therapies as we start using these emerging strategies to maximize our outcomes for the patients.

Don’t miss two additional resources that complement this program: an interactive primary treatment dosing guide; and a patient education handout. Click the Documents tab above to access.

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

This program provides awareness of the frontline therapeutic options for pediatric patients. Though current treatments are efficacious, creating a greater understanding of optimizing care while minimizing long-term toxicity from chemotherapy and radiation is critical. This clinician educational program focuses on implementing anti-CD30 targeted therapies effectively to change the disease trajectory for pediatric high-risk cHL. It provides an understanding of the expected adverse event profile of the disease and the overlap with novel therapies as we start using these emerging strategies to maximize our outcomes for the patients.

Don’t miss two additional resources that complement this program: an interactive primary treatment dosing guide; and a patient education handout. Click the Documents tab above to access.

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.